Navigation Links
Oxygen Biotherapeutics, Inc. to Present at Investment Conferences in New York and Zurich
Date:8/26/2009

DURHAM, N.C., Aug. 26 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company will present at investor conferences in New York on Sept. 9 and Zurich on Sept. 10, 2009.

Kirk Harrington, senior vice president, Warfighter Division and Government Affairs, will present at the Rodman & Renshaw Annual Global Investment Conference in New York on September 9, 2009 at 2:00 p.m. eastern time.

A live, audio webcast of Harrington's presentation will be available through the Investor Relations section of the Oxygen Biotherapeutics, Inc. website. A replay will be available following the event. Webcast login information will be provided on the company website prior to the presentation.

The following day, the company chairman and CEO, Chris Stern, will present at an investor conference in Zurich. The presentation will be at the Dolder Grand Hotel and is scheduled for 5:00 p.m. in the Garden Salon. The Zurich presentation will not be webcast but will be open to interested investors.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications. More information is available at www.oxybiomed.com.


'/>"/>
SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009
2. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
3. Brain Monitor Eliminates Need for Routine Oxygen With Propofol - Friedberg's Triad Unveiled
4. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
5. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
6. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
7. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
8. Oxygen Biotherapeutics, Inc. Expands Board of Directors
9. Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
10. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
11. Finesse Introduces TruFluor(TM) DO, a Single-Use Optical Dissolved Oxygen Sensor and Transmitter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Pharma and biotech consulting firm ... director. Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, Mr. Perkins brings 14 ... more than a decade with leading market research firm, GfK. He began his ...
(Date:2/21/2017)... 21, 2017 Synthetic Biologics, Inc. (NYSE MKT: ... microbiome to protect and restore the health of patients, intends to ... 31, 2016 on Thursday, March 2, 2017, and to host a ... information for the call is as follows: U.S. (toll ... ...
(Date:2/21/2017)... ... February 21, 2017 , ... Vortex ... , a fully automated benchtop system for collecting intact circulating tumor cells (CTCs) ... at the Molecular Medicine Tri Conference (Tri-Con) Annual Meeting 2017 (February 19–24 San ...
(Date:2/21/2017)... CA (PRWEB) , ... February 21, 2017 , ... The ... prospects for their use, in multiple areas of medicine, due to their differentiating characteristics. ... division, and they have the ability to be induced to become tissue or organic-specific ...
Breaking Biology Technology:
(Date:1/30/2017)...   Invitae Corporation (NYSE: NVTA ... today announced that it will report its fourth quarter ... on Monday, February 13, 2017, and Invitae,s management team ... p.m. Eastern / 1:45 p.m. Pacific. ... financial results, guidance, and recent developments and will spend ...
(Date:1/26/2017)... 2017  Acuity Market Intelligence today released the ... Identity".  Acuity characterizes 2017 as a "breakout" year ... reflects a new understanding of the potential benefits ... digital identity are often perceived as threats to ... Principal of Acuity Market intelligence. "However, taken together ...
(Date:1/24/2017)... Biopharm Reports has carried out a ... nuclear magnetic resonance spectroscopy (NMR). This involved the ... practices, developments, trends and end-user plans over the ... opportunities. These areas include growth in the use ... innovation requirements, hyphenated NMR techniques, main suppliers of ...
Breaking Biology News(10 mins):